Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 12
Submit an article Journal homepage
285
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation

Eleanor Tarantoa Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USAView further author information
,
Robert Reddb Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USAView further author information
,
Erin Jeterc Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USAView further author information
,
Kristin McHughc Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USAView further author information
,
Jennifer L. Crombiec Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USAView further author information
,
David C. Fisherc Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USAView further author information
,
Eric Jacobsenc Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USAView further author information
,
Caron A. Jacobsonc Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USAView further author information
,
Austin I. Kimc Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USAView further author information
,
Ann S. LaCascec Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USAView further author information
,
Oreofe O. Odejidec Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USAView further author information
,
Parastoo B. Dahid Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Yago Nietoe Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Robin M. Joycef Department of Hematologic Malignancy, Beth Israel Deaconess Medical Center, Boston, MA, USAView further author information
,
Yi-Bin Cheng Hematopoietic Cell Therapy and Transplant Program, Massachusetts General Hospital, Boston, MA, USAView further author information
,
Kimberley-Jane C. Bonjoch Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USAView further author information
,
Ammar Chaudhryh Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USAView further author information
,
Alex F. Herrerah Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USAView further author information
,
Philippe Armandc Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USAView further author information
&
Reid W. Merrymanc Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USACorrespondence[email protected]
View further author information
 show all
Pages 2912-2917 | Received 24 Apr 2022, Accepted 08 Jul 2022, Published online: 07 Aug 2022

References

  • Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853–1862.
  • Armand P, Chen YB, Redd RA, et al. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019;134(1):22–29.
  • Bachier C, Schade H, Zoghi B, et al. A Phase II Single Arm Study after Autologous Stem Cell Transplantation in Patients with Hodgkin Lymphoma at Risk of Relapse or PRogression. Blood. 2021;138s1(2455).
  • Moskowitz AJ, Yahalom J, Kewalramani T, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. 2010;116(23):4934–4937.
  • Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107(1):52–59.
  • Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132(25):2639–2642.
  • Kurtz DM, Scherer F, Jin MC, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol. 2018;36(28):2845–2853.
  • Roschewski M, Dunleavy K, Pittaluga S, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015;16(5):541–549.
  • Kurtz DM, Green MR, Bratman SV, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood. 2015;125(24):3679–3687.
  • Merryman RW, Redd RA, Taranto E, et al. Prognostic value of circulating tumor DNA (ctDNA) in autologous stem cell graft and post-transplant plasma samples among patients with diffuse large B-cell lymphoma. Blood. 2020;136(Suppl. 1):22–23.
  • Küppers R, Engert A, Hansmann ML. Hodgkin lymphoma. J Clin Invest. 2012;122(10):3439–3447.
  • Oki Y, Neelapu SS, Fanale M, et al. Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach. Br J Haematol. 2015;169(5):689–693.
  • Spina V, Bruscaggin A, Cuccaro A, et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood. 2018;131(22):2413–2425.
  • Ching T, Duncan ME, Newman-Eerkes T, et al. Analytical evaluation of the clonoSEQ assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. BMC Cancer. 2020;20(1):612.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.